Phase 3 Trial Update of Trastuzumab Emtansine for Metastatic HER2-positive Breast Cancer

Share this article:

ImmunoGen announced that Roche has reported that updated results from its EMILIA Phase 3 trial show that patients treated with trastuzumab emtansine had a significant improvement in overall survival compared to those randomized to standard-of-care therapy. Also reported today was that Genentech has submitted a Biologics License Application (BLA) for trastuzumab emtansine to the FDA.

EMILIA was designed to evaluate trastuzumab emtansine for the treatment of patients with metastatic HER2-positive breast cancer who have previously received trastuzumab (Herceptin; Genentech) and a taxane. Patients enrolled were randomized to treatment with trastuzumab emtansine – used alone – or with lapatinib (Tykerb; GlaxoSmithKline) plus capecitabine (Xeloda; Roche), standard-of-care in this setting.

The first EMILIA results were reported in June 2012, and included that trastuzumab emtansine significantly improved progression-free survival compared to standard-of-care therapy and that fewer of the trastuzumab emtansine-treated patients experienced Grade 3 or higher (severe) adverse events. A previous interim analysis of overall survival demonstrated a trend towards improved overall survival in the trastuzumab emtansine-treated patients.

Trastuzumab emtansine is an antibody-drug conjugate (ADC) comprised of the antibody trastuzumab and the chemotherapy DM1 attached together using a stable linker. It is designed to target and inhibit HER2 signaling and deliver the chemotherapy directly inside HER2-positive cancer cells.   

For more information call (781) 895-0600 or visit www.immunogen.com.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs